Greene et al. [48] recently proposed that combining SGLT2 inhibitors with angiotensin receptor–neprilysin inhibitors (ARNIs) may lower the risk of hyperkalemia and reduce the likelihood of discontinuing mineralocorticoid receptor antagonists (MRAs). This evidence concerns the gene NR3C2 and Hyperkalemia.